Program

Program Schedule

Schedule information is subject to change. Last updated 16 April 2025.

Thursday, 5 June

Hosted at the University of Chicago Gleacher Center

Time	Session
7:00 a.m.	Registration Open & Breakfast Served
8:00 a.m. - 12:00 p.m.	Session 1: Advances in Cancer Immunotherapy™: A Focus on Interventional Oncology, presented in collaboration with the Society for Immunotherapy of Cancer (SITC). Welcome and Relevant SITC Resources Robert Lewandowski, MD, FSIR, and Richard S. Finn, MD Interventional Oncology: From A to Y (ablation to Y90) Robert Lewandowski, MD, FSIR History of Immuno-Oncology: How Did We Get Where We Are? Tak Mak, MD, PhD, DSc, FRSC Intersection of Immuno-Oncology and IO Rahul A. Sheth, MD, FSIR How Are We Doing? Review of the Level 1 Evidence Adam Burgyone, MD, PhD Filling the Gaps: Where Do We Go From Here? Richard S. Finn, MD The Abscopal Effect: Is It Real? Tim F. Greten, MD Assessing Response to IO and LRT: RECIST, mRECIST, irRECIST and More Beau Toskich, MD Patients Hurdles and How to Overcome Sarah Manes, MS Discussion All session faculty Faculty Panel
12:00 - 1:00 p.m.	Lunch
1:00 - 2:15 p.m.	Session 2: Interventional Oncology: Transarterial Therapies Primer Moderators: TBD Chemoembolization: Current State of the Science Kelvin Hong, MBBCH Radioembolization: Radiation Basics of Y90 S. Cheenu Kappadath, PhD, FAAPM Resin Microsphere Dosimetry Marnix Lam, MD, PhD Glass Microsphere Dosimetry Christopher D. Malone, MD Discussion All session faculty
2:15 - 2:30 p.m.	Break
2:30 - 4:30 p.m.	Session 3: Biomarkers Moderators: Terence P. Gade, MD, PhD, (IO) and Amit Singal, MD (Medical Oncology) Keynote: How Does Immunotherapy Fit with Locoregional Therapies Amit Singal, MD Immunological Effects of Local Therapies in the Tumor Microenvironment Rony Avritscher, MD Unraveling Mechanisms of Resistance to Immunotherapy in HCC Luciane Tsukamoto Kagohara, PhD Imaging Biomarkers of Response to Immuotherapy in Liver Cancer Aliya Qayyum, MD Minimal Residual Disease after TACE Renumathy Dhanasekaran, MD Discussion All session faculty
4:30 - 4:45 p.m.	Break
4:45 - 5:45 p.m.	Session 4: Sequencing Moderators: Thomas Helmberger, MD, (IO) and Amit Singal, MD (Medical Oncology) Clinical Rationale for Different Sequencing Strategies Tim F. Greten, MD Impact of Various Interventional Modalities on Sequencing Rationale Terence P. Gade, MD, PhD Tumor Heterogeneity and Combination Therapies Luciane Tsukamoto Kagohara, PhD Managing Adverse Event of Combination Therapies Adam Burgoyne, MD, PhD Discussion All session faculty
5:45 - 6:45 p.m.	Reception

Friday, 6 June

Hosted at the Hyatt Centric-Chicago Magnificent Mile and in collaboration with the International Liver Cancer Association (ILCA) Single Topic Workshop

Time	Session
7:00 a.m.	Registration Open & Breakfast Served
8:00 - 9:30 a.m.	Session 5: Combination Therapies (IO + IO) Moderators: Edward Kim, MD, FSIR, (IO) and Stephen L. Chan, MBBS, MD, FRCP, FHKCP, FHKAM (Hepatology) EMERALD-1 and LEAP-012 Lingling Du, MD Will Combination Therapy Impact My Practice: Oncology Perspective Stephen L. Chan, MBBS, MD, FRCP, FHKCP, FHKAM Will Combination Therapy Impact My Practice: Hepatology Perspective Anjana Pillai, MD Will Combination Therapy Impact My Practice: Surgical Perspective Myron E. Schwartz, MD TARE: Ongoing Trials and IR Perspective of EMERALD-1 and LEAP-12 Christopher D. Malone, MD Discussion All session faculty
9:30 - 9:45 a.m.	Break
9:45 - 10:30 a.m.	Session 6: TARE or... Moderators: Robert J. Lewandowski, MD, FSIR, Nora Tobori, MD Solitary HCC: Ablative SBRT Stanley Liauw, MD Solitary HCC: Radiation Segmentectomy Beau Toskich, MD BTC: HAI Pump Alice Wei, MD, MSc BTC: TARE William Rilling, MD, FSIR Multifocal Bilobar HCC: Systemic Therapy Alone William P. Harris, MD Multifocal Bilobar HCC: TACE Kelvin Hong, MBBCH Multifocal Bilobar HCC: TARE Nima Kokabi, MD Discussion All session faculty
10:30 - 10:45 a.m.	Break
10:45 a.m. - 12:30 p.m.	Session 7: Practical y90 Moderators: Siddharth A. Padia, MD, and Robert J. Lewandowski, MD, FSIR Radiation Lobectomy Robert J. Lewandowski, MD, FSIR Flow Diversion: What is it and Why? Beau Toskich, MD Extra-Hepatic Supply Kirema Garcia-Reyes, MD High Lung Shunts John D. Louie, MD Lessons Learned from the European Perspective of TARE Thomas Helmberger, MD Lessons Learned from the Korean Perspective of TARE Jin Woo Choi, MD, PhD Vascular Invasion in the Era of Immunotherapy Siddharth A. Padia, MD Discussion All session faculty
12:30 - 1:30 p.m.	Lunch
1:30 - 2:50 p.m.	Session 8: Multidisciplinary Case Review 1: Curative Intent Moderator: Riad Salem, MD, MBA HCC: Solitary HCC Beyond T2 with Elevated AFP Myron E. Schwartz, MD HCC: Multi-focal within Downstaging Criteria Kelvin Hong, MBBCH BTC: Large Central Tumor Daniel B. Brown, MD, FSIR HCC: Unilobar VP3 Invasion Stephen L. Chan, MBBS, MD, FRCP, FHKCP, FHKAM Stanley Liauw, MD
2:50 - 3:00 p.m.	Break
3:00 - 4:20 p.m.	Session 9: Multidisciplinary Case Review 2: Palliative Intent Moderator: Siddarth A. Padia, MD HCC: Infiltrative HCC with Elevated AFP HCC: Large Solitary Tumor Anjana Pillai, MD HCC: Unilobar with Pulmonary Mets Jin Woo Choi, MD, PhD BTC: Recurrence Post-resection Beau Toskich, MD William P. Harris, MD; Alice Wei, MD Stanley Liauw, MD
4:30	Adjourn